This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Fed's FOMC Meeting in Focus
by Zacks Equity Research
Fed's FOMC Meeting in Focus.
Housing Data Better than Expected on Growth in Northeast
by Mark Vickery
Housing Starts came in at 1.62 million, higher than the 1.55 million estimate, which happened to be the headline number for July.
Pfizer's (PFE) COVID-19 Vaccine Successful in Children Study
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Comirnaty generates non-inferior immune response in children aged 5 to 11 years in pivotal pediatric study compared to the immune response in adults.
FDA Panel Vetoes PFE/BNTX Third Jab for All, Vaccine Stocks Down
by Kinjel Shah
Pfizer (PFE) and Moderna (MRNA) are the only two companies that have submitted data and are seeking approval for a booster or "third" dose of their COVID-19 vaccines.
The Zacks Analyst Blog Highlights: NVIDIA, Johnson & Johnson, Toyota, Merck and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NVIDIA, Johnson & Johnson, Toyota, Merck and 3M
Johnson & Johnson (JNJ) Stock Moves -0.12%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $165.22 in the latest trading session, marking a -0.12% move from the prior day.
Top Research Reports for NVIDIA, Johnson & Johnson & Toyota
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Johnson & Johnson (JNJ), and Toyota Motor Corporation (TM).
Theravance (TBPH) to Cut Workforce, Hypotension Study Fails
by Zacks Equity Research
Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%. Stocks falls.
Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet
by Zacks Equity Research
Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Emergent (EBS) Inks COVID-19 Manufacturing Deal With Providence
by Zacks Equity Research
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
by Zacks Equity Research
AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.
Endo (ENDP) Gains on Settlement of Opioid Cases in New York for $50M
by Zacks Equity Research
Endo (ENDP) stock gains following the settlement of three opioid cases in the New York State in exchange for a total payment of $50 million.
Will COVID-19 Vaccines for Children be Available by Year-End?
by Zacks Equity Research
The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.
Johnson & Johnson (JNJ) Stock Moves -0.65%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $166.97, moving -0.65% from the previous trading session.
Lilly's (LLY) Jardiance Gets Breakthrough Therapy Tag for HFpEF
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Lilly's (LLY) Jardiance for heart failure with preserved ejection fraction (HFpEF).
Decoding Mu Variant: The Next Big Threat in COVID-19 Cases?
by Zacks Equity Research
Another variant of the coronavirus, Mu Variant, is up on the WHO-identified list. One study finds its potential to be highly resistant to the COVID-19 vaccines.
Stock Market News for Sep 10, 2021
by Zacks Equity Research
U.S. stock markets closed lower on Thursday as investors await the decision of the U.S. Federal Reserve with regard to the monetary policy.
Moderna (MRNA) Inks Deal to Develop Ultra-Rare Disease Therapy
by Zacks Equity Research
Moderna (MRNA) inks a collaboration deal with the Institute for Life Changing Medicines to develop a free of charge mRNA-based therapy to treat Crigler-Najjar Syndrome type 1, an ultra-rare disease.
Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca
4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage. JNJ, RHHBY, PFE and AZN are worth retaining in your portfolio.
Moderna (MRNA) Seeks Authorization for Booster Dose in Europe
by Zacks Equity Research
Moderna (MRNA) is developing a booster dose of its COVID-19 vaccine, mRNA-1273, for enhancing protection against infection in individuals.
Supernus (SUPN) Seeks Label Expansion for ADHD Drug Qelbree
by Zacks Equity Research
The FDA accepts Supernus' (SUPN) regulatory application seeking label application for Qelbree to include adult patients with ADHD.
Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates
by Kinjel Shah
FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.
Moderna (MRNA) Gives First COVID Jab Booster Data to the FDA
by Zacks Equity Research
Moderna's (MRNA) booster dose of COVID-19 vaccine elicits antibody levels that were much higher than that seen after the two-dose primary schedule.